跳转至内容
Merck
CN

D-003

1,3-二硝基甘油 溶液

100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C3H6N2O7
化学文摘社编号:
分子量:
182.09
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-835-2
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

ASIGVDLTBLZXNC-UHFFFAOYSA-N

InChI

1S/C3H6N2O7/c6-3(1-11-4(7)8)2-12-5(9)10/h3,6H,1-2H2

SMILES string

OC(CO[N+]([O-])=O)CO[N+]([O-])=O

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

100 μg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

正在寻找类似产品? 访问 产品对比指南

General description

1,3-Dinitroglycerin is a major plasma metabolite of the pharmaceutical vasodilator nitroglycerin. This Certified Spiking Solution® is suitable for use in chromatography or mass spectrometry-based applications in pharmaceutical research or clinical toxicology. Nitroglycerin is used to treat heart conditions such as angina and chronic heart failure.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

FlameExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

R C Jewell et al.
Pharmaceutical research, 9(10), 1284-1289 (1992-10-01)
The FDA Cooperative Efficacy Study of transdermal nitroglycerin utilized a combination of marketed products over a wide dose range. Unfortunately, plasma nitroglycerin concentrations were not determined. The current study was conducted to assess plasma nitrate concentrations after transdermal doses of
M Gumbleton et al.
Journal of pharmacokinetics and biopharmaceutics, 21(5), 515-532 (1993-10-01)
The organic nitrate 1,3-glyceryl dinitrate (1,3-GDN) is one of the primary dinitrate metabolites of the antianginal agent nitroglycerin (GTN). Investigational New Drug Approval was sought to administer oral solution doses of 1,3-GDN to a small number (n = 3) of
T Fujii et al.
Biological & pharmaceutical bulletin, 19(8), 1093-1096 (1996-08-01)
Nitroglycerin (GTN) has been used as the drug of choice in the treatment of angina pectoris. It has been shown that some glutathione S-transferases (GSTs) catalyze the metabolic conversion from GTN to glyceryl dinitrates (GDNs). In this study, we examined
D T Lau et al.
Biochemical pharmacology, 43(10), 2247-2254 (1992-05-28)
The effects of sulfobromophthalein (SBP) and ethacrynic acid (ECA), both inhibitors of glutathione S-transferase (GST), or glyceryl trinitrate (GTN)-induced vasorelaxation were investigated in rabbit aortic strips. The aortic strips were pre-contracted with phenylephrine, followed by relaxation with 0.5 microM GTN
B Auclair et al.
Therapeutic drug monitoring, 20(6), 607-611 (1998-12-16)
The purpose of this study was to assess the ability of our previously constructed pharmacokinetic (PK) model to describe nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN) plasma concentrations after a single-dose application of a GTN transdermal matrix delivery system. GTN

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持